EUVIMEDEUVIMED entdecken
Crossref

Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma

Milre M Matherne iD, John C Panetta iD, Jaclyn Hopp, Hiroto Inaba iD, Ching-Hon Pui iD, Seth E Karol iD, M Brooke Bernhardt iD, Hope D Swanson iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-05 · 46 (5)

DOI: 10.1002/phar.70146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 21.04.2026. Verfasst von Milre M Matherne und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Asparaginase, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: American Lebanese Syrian Associated Charities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment for pediatric acute lymphoblastic leukemia includes asparaginase as an integral component of therapy. Hypersensitivity reactions or silent inactivation to Escherichia coli ( E. coli ) formulations may necessitate switching to Erwinia ‐based asparaginase (asparaginase Erwinia chrysanthemi [E‐ASP] or recombinant asparaginase Erwinia chrysanthemi [R‐ASP]). However, pharmacokinetic data for R‐ASP in pediatrics remain limited, and recommended dosing schedules present logistical challenges. We investigated if adherence to approved dosing regimens for R‐ASP is necessary to achieve optimal pharmacokinetic exposure in pediatric patients with leukemia or lymphoma.

Methods

We performed a single institution, retrospective review of pharmacokinetic data in patients who received R‐ASP between October 1, 2021 and September 30, 2024. A one‐compartment pharmacokinetic model with first‐order absorption and elimination was used to evaluate asparaginase pharmacokinetic activity. The pharmacokinetic model was used to determine if the labeled dosing window for R‐ASP is required to achieve effective asparagine depletion.

Results

Twenty‐six patients with 115 measurements of serum asparaginase activity (SAA) were included in the analysis. Based on model simulations from our pediatric patient data, maintaining SAA ≥ 0.1 IU/mL in 90% of patients throughout the dosing interval with R‐ASP 25/25/50 mg/m 2 administered intramuscularly on Monday, Wednesday, and Friday requires precise timing. Specifically, the Friday 50 mg/m 2 dose must be administered within 58 h of the Wednesday morning dose to sustain therapeutic activity. Additionally, only 62.5% of patients maintained SAA ≥ 0.1 IU/mL at 72 h after the last dose with R‐ASP 25 mg/m 2 administered intramuscularly on a Monday, Wednesday, and Friday dosing schedule.

Conclusion

Overall, our findings support the importance of adhering closely to the United States Food and Drug Administration approved dosing schedule for R‐ASP to ensure adequate asparaginase activity in pediatric patients with leukemia or lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsparaginaseAntineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphomaHumansChildRetrospective StudiesChild, PreschoolRecombinant ProteinsMaleFemaleDickeya chrysanthemiErwiniaAdolescentDrug Administration Schedule

Stichwörter der Autor:innen

asparaginaseasparaginase erwinia chrysanthemi recombinantpharmacokinetics

Substanzen

AsparaginaseAntineoplastic AgentsRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

ORCID-Profile: Milre M Matherne, John C Panetta, Hiroto Inaba, Ching-Hon Pui, Seth E Karol, M Brooke Bernhardt, Hope D Swanson

Förderung

  • American Lebanese Syrian Associated Charities

Zitieren

APA

Matherne, M. M., Panetta, J. C., Hopp, J., Inaba, H., Pui, C. H., Karol, S. E., Bernhardt, M. B., & Swanson, H. D. (2026). Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(5). https://doi.org/10.1002/phar.70146

Vancouver

Matherne MM, Panetta JC, Hopp J, Inaba H, Pui CH, Karol SE, et al. Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(5). doi:10.1002/phar.70146

BibTeX
@article{Matherne2026,
  author = {Matherne, Milre M and Panetta, John C and Hopp, Jaclyn and Inaba, Hiroto and Pui, Ching-Hon and Karol, Seth E and Bernhardt, M Brooke and Swanson, Hope D},
  title = {Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {5},
  doi = {10.1002/phar.70146}
}
Kostenlos starten →